Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 5;15(1):48.
doi: 10.1186/s12969-017-0177-x.

Design and implementation of a decision aid for juvenile idiopathic arthritis medication choices

William B Brinkman  1 , Ellen A Lipstein  2 , Janalee Taylor  2 , Pamela J Schoettker  2 , Katherine Naylor  3 , Karla Jones  4 , Sheetal S Vora  5 , Catherine C Mims  6 , Elizabeth Roth-Wojcicki  7 , Beth Gottlieb  8 , Nancy Griffin  2 , Carole Lannon  2 , Esi Morgan  2
Affiliations

Design and implementation of a decision aid for juvenile idiopathic arthritis medication choices

William B Brinkman et al. Pediatr Rheumatol Online J. .

Abstract

Background: Randomized trials have demonstrated the efficacy of patient decision aids to facilitate shared decision making in clinical situations with multiple medically reasonable options for treatment. However, little is known about how best to implement these tools into routine clinical practice. In addition, reliable implementation of decision aids has been elusive and spread within pediatrics has been slow. We sought to develop and reliably implement a decision aid for treatment of children with juvenile idiopathic arthritis.

Methods: To design our decision aid, we partnered with patient, parent, and clinician stakeholders from the Pediatric Rheumatology Care and Outcomes Improvement Network. Six sites volunteered to use quality improvement methods to implement the decision aid. Four of these sites collected parent surveys following visits to assess outcomes. Parents reported on clinician use of the decision aid and the amount of shared decision making and uncertainty they experienced. We used chi-square tests to compare eligible visits with and without use of the decision aid on the experience of shared decision making and uncertainty.

Results: After 18 rounds of testing and revision, stakeholders approved the decision aid design for regular use. Qualitative feedback from end-users was positive. During the implementation project, the decision aid was used in 35% of visits where starting or switching medication was discussed. Clinicians used the decision aid as intended in 68% of these visits. The vast majority of parents reported high levels of shared decision making following visits with (64/76 = 84%) and without (80/95 = 84%) use of the decision aid (p = 1). Similarly, the vast majority of parents reported no uncertainty following visits with (74/76 = 97%) and without (91/95 = 96%) use of the decision aid (p = 0.58).

Conclusions: Although user acceptability of the decision aid was high, reliable implementation in routine clinical care proved challenging. Our parsimonious approach to outcome assessment failed to detect a difference between visits with and without use of our aid. Innovative approaches are needed to facilitate use of decision aids and the assessment of outcomes.

Keywords: Decision aids; Juvenile idiopathic arthritis; Patient education; Shared decision-making.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Key driver diagram
See this image and copyright information in PMC

References

    1. Rochette E, Duche P, Merlin E. Juvenile idiopathic arthritis and physical activity: possible inflammatory and immune modulation and tracks for interventions in young populations. Autoimmun Rev. 2015;14(8):726–734. doi: 10.1016/j.autrev.2015.04.007. - DOI - PubMed
    1. Tugwell P, Singh J, Wells G. Biologics for rheumatoid arthritis. BMJ. 2011;343:d4027. doi: 10.1136/bmj.d4027. - DOI - PubMed
    1. Lipstein E, Lovell D, Denson L, Moser D, Saeed S, Dodds C, et al. Parents’ information needs in tumor necrosis factor-α inhibitor treatment decisions. J Pediatr Gastroenterol Nutr. 2013;56(3):244–250. doi: 10.1097/MPG.0b013e31827496c3. - DOI - PubMed
    1. Lipstein E, Britto M. Evolution of pediatric chronic disease treatment decisions: a qualitative, longitudinal view of parents’ decision-making process. Med Decis Mak. 2015;35(6):703–713. doi: 10.1177/0272989X15581805. - DOI - PMC - PubMed
    1. Barry M, Edgman-Levitan S. Shared decision making - pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–781. doi: 10.1056/NEJMp1109283. - DOI - PubMed

MeSH terms